Trial Condition(s):

Thromboembolism

SALTO - Epidemiological study on compliance and treatment satisfaction (SALTO)

Bayer Identifier:

14343

ClinicalTrials.gov Identifier:

NCT00911001

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Patients that are on total knee/hip replacement initiate prophylaxis treatment on the hospital ground. Once they leave the hospital, as outpatients they continue with the treatment at least during two consecutive weeks. Patients will be instructed to follow treatment recommendations (either LMWH or oral treatment, at physician discretion) and to come back to the surgeon after that period. At that visit, the Treatment Satisfaction Questionaire with Medication (TSQM) test as well as the Moriski-Green Questionaire (measures compliance with medication) will be answer by the patient. TSQM is an self administered validated scale (validated also in spanish) that measures in a generic way the treatment satisfaction to a treatment. Morinski-Green test will be used to measure the compliance degree on medication.

Inclusion Criteria
- Patients in antithrombotic prophylaxis treatment after total knee/hip replacement. This is an epidemiological study where the patients to be included will be those that are treated with antithrombotics as out-patients in real life conditions.
Exclusion Criteria
- Patients who has been previously treated with injectable antithrombotic treatments.
 - Diabetic patients treated with insulin.
 - Patients who do not sign Informed Consent Form.

Trial Summary

Enrollment Goal
480
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
No Drug
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Spain

Status
Completed
 

Trial Design